R
96.31
-1.02 (-1.05%)
| 前收盘价格 | 97.33 |
| 收盘价格 | 97.84 |
| 成交量 | 1,431,551 |
| 平均成交量 (3个月) | 3,378,436 |
| 市值 | 18,618,630,144 |
| 价格/销量 (P/S) | 9.04 |
| 股市价格/股市净资产 (P/B) | 4.58 |
| 52周波幅 | |
| 利润日期 | 5 Nov 2025 |
| 稀释每股收益 (EPS TTM) | -4.01 |
| 总债务/股东权益 (D/E MRQ) | 6.46% |
| 流动比率 (MRQ) | 13.46 |
| 营业现金流 (OCF TTM) | -591.31 M |
| 杠杆自由现金流 (LFCF TTM) | -349.13 M |
| 资产报酬率 (ROA TTM) | -23.09% |
| 股东权益报酬率 (ROE TTM) | -36.68% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Revolution Medicines, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
0.3
| 分析师共识 | 3.0 |
| 内部交易活动 | 3.0 |
| 价格波动 | -0.5 |
| 技术平均移动指标 | -3.5 |
| 技术振荡指标 | -0.5 |
| 平均 | 0.30 |
|
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 2.02% |
| 机构持股比例 | 105.87% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 170.00 (Stifel, 76.51%) | 购买 |
| 中 | 144.00 (49.52%) | |
| 低 | 120.00 (Piper Sandler, 24.60%) | 购买 |
| 平均值 | 143.78 (49.29%) | |
| 总计 | 9 购买 | |
| 平均价格@调整类型 | 108.44 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Needham | 26 Feb 2026 | 145.00 (50.56%) | 购买 | 102.15 |
| Piper Sandler | 26 Feb 2026 | 120.00 (24.60%) | 购买 | 102.15 |
| Wells Fargo | 26 Feb 2026 | 144.00 (49.52%) | 购买 | 102.15 |
| JP Morgan | 02 Feb 2026 | 122.00 (26.67%) | 购买 | 97.16 |
| Oppenheimer | 27 Jan 2026 | 150.00 (55.75%) | 购买 | 99.82 |
| Stifel | 22 Jan 2026 | 170.00 (76.51%) | 购买 | 118.81 |
| RBC Capital | 21 Jan 2026 | 140.00 (45.36%) | 购买 | 117.53 |
| Guggenheim | 20 Jan 2026 | 160.00 (66.13%) | 购买 | 116.22 |
| Mizuho | 13 Jan 2026 | 143.00 (48.48%) | 购买 | 119.95 |
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| ANDERS JACK | 102.02 | - | 20,200 | 2,060,804 |
| ANDERSON ELIZABETH M | 101.19 | 101.19 | 0 | 0 |
| CISLINI JEFF | 102.02 | - | 14,500 | 1,479,290 |
| GOLDSMITH MARK A | 102.02 | 101.62 | 21,100 | 2,167,022 |
| HORN MARGARET A | 102.02 | - | 21,100 | 2,152,622 |
| KELSEY STEPHEN MICHAEL | 102.02 | - | 21,100 | 2,152,622 |
| WANG XIAOLIN | 102.02 | - | 15,100 | 1,540,502 |
| WEI LIN | 102.02 | - | 15,100 | 1,540,502 |
| 累积净数量 | 128,200 | |||
| 累积净值 ($) | 13,093,364 | |||
| 累积平均购买 ($) | 101.92 | |||
| 累积平均卖出 ($) | 101.48 | |||
| 内部人员交易波幅 ($) | ||||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| ANDERSON ELIZABETH M | 董事 | 04 Mar 2026 | 处理 (-) | 15,000 | 101.19 | 1,517,850 |
| ANDERSON ELIZABETH M | 董事 | 04 Mar 2026 | 获得 (+) | 15,000 | 101.19 | 1,517,850 |
| GOLDSMITH MARK A | 职员 | 02 Mar 2026 | 自动卖出 (-) | 30,000 | 101.62 | 3,048,600 |
| GOLDSMITH MARK A | 职员 | 02 Mar 2026 | 卖 (-) | 6,000 | 101.62 | 609,720 |
| GOLDSMITH MARK A | 职员 | 02 Mar 2026 | 执行期权 | 30,000 | - | - |
| ANDERS JACK | 职员 | 01 Mar 2026 | 获得 (+) | 20,200 | 102.02 | 2,060,804 |
| CISLINI JEFF | 职员 | 01 Mar 2026 | 获得 (+) | 14,500 | 102.02 | 1,479,290 |
| HORN MARGARET A | 职员 | 01 Mar 2026 | 获得 (+) | 21,100 | 102.02 | 2,152,622 |
| GOLDSMITH MARK A | 职员 | 01 Mar 2026 | 获得 (+) | 57,100 | 102.02 | 5,825,342 |
| KELSEY STEPHEN MICHAEL | 职员 | 01 Mar 2026 | 获得 (+) | 21,100 | 102.02 | 2,152,622 |
| WEI LIN | 职员 | 01 Mar 2026 | 获得 (+) | 15,100 | 102.02 | 1,540,502 |
| WANG XIAOLIN | 职员 | 01 Mar 2026 | 获得 (+) | 15,100 | 102.02 | 1,540,502 |
| 显示更多 | ||||||
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合